SEEL
Price:
$0.228
Market Cap:
$1.59M
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients ...[Read more]
Industry
Biotechnology
IPO Date
1999-04-19
Stock Exchange
NASDAQ
Ticker
SEEL
According to Seelos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.01. This represents a change of -100.70% compared to the average of -1.42 of the last 4 quarters.
The mean historical PE Ratio of Seelos Therapeutics, Inc. over the last ten years is -12.70. The current 0.01 PE Ratio has changed -107.87% with respect to the historical average. Over the past ten years (40 quarters), SEEL's PE Ratio was at its highest in in the March 2017 quarter at 62.85. The PE Ratio was at its lowest in in the December 2016 quarter at -2024.21.
Average
-12.70
Median
-16.48
Minimum
-437.23
Maximum
545.87
Discovering the peaks and valleys of Seelos Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 581.33%
Maximum Annual PE Ratio = 545.87
Minimum Annual Increase = -492.34%
Minimum Annual PE Ratio = -437.23
Year | PE Ratio | Change |
---|---|---|
2023 | -1.43 | -81.20% |
2022 | -7.59 | -56.77% |
2021 | -17.57 | -40.39% |
2020 | -29.47 | 581.33% |
2019 | -4.33 | -71.90% |
2018 | -15.40 | -102.82% |
2017 | 545.87 | -492.34% |
2016 | -139.13 | 570.66% |
2015 | -20.75 | -95.26% |
2014 | -437.23 | -66.23% |
The current PE Ratio of Seelos Therapeutics, Inc. (SEEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.86
5-year avg
-12.08
10-year avg
-12.70
Seelos Therapeutics, Inc.’s PE Ratio is greater than Atai Life Sciences N.V. (-3.29), greater than Mind Medicine (MindMed) Inc. (-4.19), greater than GH Research PLC (-12.25), greater than Freeline Therapeutics Holdings plc (-0.57), greater than Cybin Inc. (-2.71), greater than Awakn Life Sciences Corp. (-1.47), greater than Pulmatrix, Inc. (-0.67), greater than Capricor Therapeutics, Inc. (-4.65), greater than Akari Therapeutics, Plc (-1.55), greater than Diffusion Pharmaceuticals Inc. (-0.00), greater than Soleno Therapeutics, Inc. (-28.67), greater than Eliem Therapeutics, Inc. (-3.49), greater than Opthea Limited (-1.11), greater than Molecular Partners AG (-2.67), greater than Edgewise Therapeutics, Inc. (-14.14), greater than iTeos Therapeutics, Inc. (-5.43), less than TRACON Pharmaceuticals, Inc. (0.03), greater than Histogen Inc. (-0.10), greater than Entera Bio Ltd. (-7.78), greater than Tempest Therapeutics, Inc. (-0.88), greater than Better Therapeutics, Inc. (-0.00),
Company | PE Ratio | Market cap |
---|---|---|
-3.29 | $199.68M | |
-4.19 | $483.69M | |
-12.25 | $428.19M | |
-0.57 | $28.28M | |
-2.71 | $159.69M | |
-1.47 | $4.43M | |
-0.67 | $7.30M | |
-4.65 | $132.76M | |
-1.55 | $35.02M | |
-0.00 | $8.98M | |
-28.67 | $1.89B | |
-3.49 | $495.57M | |
-1.11 | $444.73M | |
-2.67 | $182.90M | |
-14.14 | $1.64B | |
-5.43 | $540.52M | |
0.03 | $194.57K | |
-0.10 | $939.79K | |
-7.78 | $65.02M | |
-0.88 | $31.26M | |
-0.00 | $5.45K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Seelos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Seelos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Seelos Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Seelos Therapeutics, Inc. (SEEL)?
What is the highest PE Ratio for Seelos Therapeutics, Inc. (SEEL)?
What is the 3-year average PE Ratio for Seelos Therapeutics, Inc. (SEEL)?
What is the 5-year average PE Ratio for Seelos Therapeutics, Inc. (SEEL)?
How does the current PE Ratio for Seelos Therapeutics, Inc. (SEEL) compare to its historical average?